Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) to Overweight, 'clarity on 2026 growth and no major near-term headwinds for the stock'
Go back to Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) to Overweight, 'clarity on 2026 growth and no major near-term headwinds for the stock'| (NASDAQ: MDGL) | Delayed: 507.56 +0.19 (0.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $507.37 | 52 Week High | $18.24 | |||
| Open | $504.34 | 52 Week Low | $6.60 | |||
| Day High | $509.89 | P/E | N/A | |||
| Day Low | $494.90 | EPS | $0.00 | |||
| Volume | 234,656 | |||||

